Financials data is unavailable for this security.
View more
Year on year Abbott Laboratories 's revenues fell -8.12% from 43.65bn to 40.11bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 6.93bn to 5.72bn, a -17.45% decrease.
| Gross margin | 55.43% |
|---|---|
| Net profit margin | 13.65% |
| Operating margin | 15.82% |
| Return on assets | 7.59% |
|---|---|
| Return on equity | 14.53% |
| Return on investment | 9.44% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Abbott Laboratories fell by 2.99bn. However, the company earned 7.26bn from its operations for a Cash Flow Margin of 18.10%. In addition the company used 3.13bn on investing activities and also paid 7.09bn in financing cash flows.
| Cash flow per share | 5.03 |
|---|---|
| Price/Cash flow per share | 23.00 |
| Book value per share | 22.60 |
|---|---|
| Tangible book value per share | 4.70 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.68 |
|---|---|
| Quick ratio | 1.18 |
| Total debt/total equity | 0.3753 |
|---|---|
| Total debt/total capital | 0.2716 |
More ▼
Growth rates in USD
SmartText is unavailable
| Div yield(5 year avg) | 1.53% |
|---|---|
| Div growth rate (5 year) | 12.74% |
| Payout ratio (TTM) | 67.79% |
| EPS growth(5 years) | 18.64 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 8.06 |
More ▼
